<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:chebi fb="1" ids="35705">immunosuppressant</z:chebi> <z:chebi fb="2" ids="2948">azathioprine</z:chebi> (AZA) is widely used in the treatment of <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel disease</z:e> (IBD) for both inducing and maintaining remission </plain></SENT>
<SENT sid="1" pm="."><plain>However, the adverse effects of AZA can often necessitate a dose reduction or discontinuation </plain></SENT>
<SENT sid="2" pm="."><plain>Bone marrow suppression is one of the most serious complications with AZA treatment </plain></SENT>
<SENT sid="3" pm="."><plain>On the other hand, some reports have suggested that <z:hpo ids='HP_0001875'>neutropenia</z:hpo> during AZA therapy reduced the relapse rates of IBD patients, and there have been some cases where eradication of the sensitized leukocytes by leukapheresis or bone marrow transplantation improved the IBD, which may explain the relevant role of <z:hpo ids='HP_0001875'>neutropenia</z:hpo> in controlling disease activity </plain></SENT>
<SENT sid="4" pm="."><plain>This report describes the case of a 22-year-old male patient who had Crohn's <z:hpo ids='HP_0002583'>colitis</z:hpo> and complicated perianal <z:mpath ids='MPATH_70'>fistulas</z:mpath> that required immunosuppression; he achieved endoscopically determined remission and showed accelerated mucosal healing as well as clinical remission following the AZA-induced <z:hpo ids='HP_0001876'>pancytopenia</z:hpo> </plain></SENT>
</text></document>